Therapeutic advances in guideline‐directed medical therapy for heart failure: the idealistic versus the pragmatic truth for vulnerable patients

Click to increase image sizeClick to decrease image size

Key take home points

• Increasing complexity for treatment of patients with HF

• Newer treatments now supported by guideline recommendations are expensive and certain patient population will suffer as a result (i.e. underserved, uninsured)

• Focus should be on ensuring access to these life-saving medications

• Increasing affordability and transparency of costs should be a priority

Declaration of funding

No funding was received for the production of this manuscript.

Declaration of any financial/other conflicts of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.